Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 0.66 |
| ▸ | ITGAV | P06756 | 10/20 | 0.66 |
| ▸ | ITGB1 | P05556 | 7/20 | 0.66 |
| ▸ | ITGB6 | P18564 | 3/20 | 0.66 |
| ▸ | ITGB5 | P18084 | 3/20 | 0.66 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.62 |
| ▸ | ITGA5 | P08648 | 3/20 | 0.59 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.55 |
| ▸ | MDM4 | O15151 | 1/20 | 0.55 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.55 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.54 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6773037 | 0.99 | ITGB3 (0.65) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6771845 | 0.96 | ITGB3 (0.71) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL18077406 | 0.84 | ITGB1 (0.59) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL7264806 | 0.82 | ITGB3 (0.94) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL24743258 | 0.81 | HDAC3 (0.60) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6779332 | 0.81 | ITGB3 (0.53) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL2037116 | 0.80 | ITGB3 (0.70) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL4530820 | 0.80 | FFAR1 (0.88) | FFAR1S1PR1S1PR3S1PR5 | |
| SCHEMBL7260180 | 0.80 | ITGB3 (0.57) | ITGB3ITGAVITGB1ITGB6ITGB5 | |
| SCHEMBL6773034 | 0.80 | ITGB3 (0.52) | ITGB3ITGAVITGB1ITGB6ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833366-B1 | Dihydrostilbene alkanoic acid derivatives | PHARMACIA CORPORATION | 2004-12-21 | — | — | US | claimed |
| US-6720315-B2 | FOR INHIBITING BONE RESORPTION, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR METASTASIS, SOLID TUMOR GROWTH, ANGIOGENESIS, MACULAR DEGENERATION AND DIABETIC RETINOPATHY RETINOPATHY | PHARMACIA CORPORATION | 2004-04-13 | — | — | US | claimed |
| EP-1289959-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | Pharmacia Corporation (US) | 2003-03-12 | — | — | EP | claimed |
| US-20020099209-A1 | Dihydrostilbene alkanoic acid derivatives | PHARMACIA CORPORATION | 2002-07-25 | — | — | US | claimed |
| WO-2001096310-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | claimed |
| US-6833366-B1 | Dihydrostilbene alkanoic acid derivatives | PHARMACIA CORPORATION | 2004-12-21 | — | — | US | disclosed |
| US-6720315-B2 | FOR INHIBITING BONE RESORPTION, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR METASTASIS, SOLID TUMOR GROWTH, ANGIOGENESIS, MACULAR DEGENERATION AND DIABETIC RETINOPATHY RETINOPATHY | PHARMACIA CORPORATION | 2004-04-13 | — | — | US | disclosed |
| EP-1289959-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | Pharmacia Corporation (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001096310-A1 | DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS | PHARMACIA CORPORATION (US) | 2001-12-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099209-A1 | Dihydrostilbene alkanoic acid derivatives | ITGA5, ITGB5, ITGB1 | ITGB3 5/4885ITGAV 12/4885ITGB1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.